Dr. Ho's primary research focuses on biomedical strategies for HIV prevention, and in particular, HIV pre-exposure prophylaxis (PrEP) and microbicide development. He conducts multiple clinical trials of PrEP and microbicides at the University of Pittsburgh Clinical Trial Unit. He was the investigator of record for the Next-PrEP Study (HPTN-069), a safety and tolerability study of maraviroc based regimens for PrEP. He is the protocol chair for MTN-033: An Open Label Randomized Phase 1 Pharmacokinetic Study of Dapivirine Gel Administered Rectally to HIV-1 Seronegative Adults. He is also the investigator of record of several other microbicide studies such as DREAM-01 (evaluation of a tenofovir enema) and MTN-026 (Dapivirine gel). Dr. Ho is the Medical Director of the Pitt Mens Study, the Pittsburgh branch of the Multicenter AIDS Cohort Study. He conducts studies of periodic PrEP use and is the principal investigator of the EpiPrEP Pilot Study, which is looking at Intermittent PrEP for HIV prevention among gay, bisexual and other men who have sex with men (msm).
Dr. Ho's clinical interests involve HIV PrEP, HIV clinical care, and general infectious diseases. He established the PrEP prophylaxis clinic at the University of Pittsburgh Medical Center in early 2013. He is also an HIV clinician and rounds on the general infectious diseases service.
- BA, Plant Biology, Cornell University, 1998
- MD, University of Maryland, 2004
- MPH, Epidemiology, Bloomberg School of Public Health, The Johns Hopkins University, 2003
- Residency, Internal Medicine, University of Pittsburgh, 2007
- Fellowship, University of Pittsburgh School of Medicine
Education & Training
Title: University of Pittsburgh MACS-WIHS CCS
Role: Director
Funding Agency: National Heart, Lung, & Blood Institute
Grant Number: U01 HL146208
Start Year: 2019
End Year: 2026
